Sohrab Shah, PhD

Chief of Computational Oncology

Share
Print
Share
Print
Sohrab Shah

Office Phone

646-608-7558

Sohrab Shah is the Chief of Computational Oncology in the Department of Epidemiology and Biostatistics. Dr. Shah received a PhD in computer science from the University of British Columbia in 2008 and developed his research program in computational biology at BC Cancer Agency and the University of British Columbia starting in 2010. His research focuses on developing and using computational methods to understand cancer evolution and treatment response. This encompasses advanced machine learning and Bayesian statistical methods to analyze and interpret large-scale datasets in cancer research. At MSK, Dr. Shah is building new and innovative capacity in computational methods across the spectrum of data-intensive research activity. This includes multimodal data integration such as genomics and imaging, high-resolution single-cell genomics, and transcriptomics. His translational focus lies in breast cancer and ovarian cancer, in which he has pioneered discovery of prognostic mutational signatures and large-scale studies of mutational landscapes and evolution of these cancers. Dr. Shah is a former Canada Research Chair, is a Komen Scholar, and holds the Nicholls-Biondi Endowed Chair in Computational Oncology at MSK.

Publications

 

  1. Campbell KR, …, Shah SP. clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Genome Biol. 2019 Mar 12;20(1):54. doi: 10.1186/s13059-019-1645-z. PubMed PMID: 30866997; PubMed Central PMCID: PMC6417140.
  2. Zhang AW, …, Shah SP. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10. PubMed PMID: 29754820.
  3. Wang YK, …, Shah SP. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24. PubMed PMID: 28436987.
  4. Zahn H, …, Shah SP, et al. Scalable whole-genome single-cell library preparation without preamplification. Nat Methods. 2017 Feb;14(2):167-173. doi: 10.1038/nmeth.4140. Epub 2017 Jan 9. PubMed PMID: 28068316.
  5. Roth A, …, Shah SP. Clonal genotype and population structure inference from single-cell tumor sequencing. Nat Methods. 2016 Jul;13(7):573-6. doi: 10.1038/nmeth.3867. Epub 2016 May 16. PubMed PMID: 27183439.
  6. McPherson A, …, Shah SP. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016 Jul;48(7):758-67. doi: 10.1038/ng.3573. Epub 2016 May 16. PubMed PMID: 27182968.
  7. Eirew P, …, Shah SP, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015 Feb 19;518(7539):422-6. doi: 10.1038/nature13952. Epub 2014 Nov 26. PubMed PMID: 25470049; PubMed Central PMCID: PMC4864027.
  8. Roth A, …, Shah SP. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014 Apr;11(4):396-8. doi: 10.1038/nmeth.2883. Epub 2014 Mar 16. PubMed PMID: 24633410; PubMed Central PMCID: PMC4864026.
  9. Shah SP, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature.  2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933. PubMed PMID: 22495314; PubMed Central PMCID: PMC3863681.

 

View a complete listing of Sohrab Shah’s publications

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sohrab Shah discloses the following relationships and financial interests:

  • Contextual Genomics Inc
    Ownership / Equity Interests; Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures